Advertise on podcast: Positive Psychiatry - with Rakesh Jain, MD

Community is ancient, but the way many of us live now makes it feel oddly out of reach. After returning from Psych Congress in New Orleans and feeling what it’s like to be “soaked in community,” I step back and ask a clinical question with huge stakes: what happens to mental health when belonging disappears, and what happens when we rebuild it on purpose? We get precise about the words we toss around. Social isolation is objective structure and frequency of contact. Loneliness is the subjective, painful gap between the connection we want and what we feel we have. Social support is the real-world resources relationships provide, and belonging is the felt sense that we count. From there, I offer a working definition of community that goes beyond crowds and followers, plus a framework you can actually use: the five C’s of community (contact, care, contribution, continuity, common purpose). It changes how we assess a patient’s relational world and how we understand why “busy” is not the same as “connected.” Then we zoom out to the evidence and the neurobiology of connection. Large studies link strong relationships to meaningful physical health outcomes, while loneliness tracks with depression, anxiety, sleep disruption, cognitive decline, and suicide risk. We unpack social pain, stress physiology, and why a graded, gentle approach works better than telling someone to “just get out more.” I also cover the dark side of community, with practical safety questions to spot groups that shame, control, or exploit. Finally, we turn assessment into action with social prescribing and a “community prescription,” including 10 practical interventions, the idea of a third place, micro-connection, peer support, and a simple seven-day experiment to create momentum.  www.JainUplift.com

A patient dies by suicide, and the clinician left behind is often handed an unspoken script: stay calm, finish the day, say nothing, document everything, and don’t let anyone see you break. We reject that script and tell the story that rarely gets told: the clinician’s story after patient suicide loss. We walk through the data on how common this is across psychiatry, therapy, nursing, trainees, and primary care, and why the “second victim” phenomenon matters for more than feelings. When grief is forced underground, it can turn into isolation, burnout, and defensive medicine that changes how we treat high-risk patients, sometimes raising risk for future harm. We also name the hard questions clinicians face right away: whether to contact the family, attend a funeral, and how to cope with scrutiny like Joint Commission sentinel event reviews, licensing concerns, and liability fears, all while trying to sleep at night. Then we get practical. We share a six-stage recovery map that helps clinicians understand what’s happening internally, plus concrete ways to support a colleague with emotional presence, specific workload help, space for meaning-making, and growth support. Finally, we make room for the most hopeful science here: post-traumatic growth after trauma, fueled by self-disclosure, healing relationships, and self-forgiveness that is neither denial nor self-excuse. www.JainUplift.com

Three numbers kick off the story: major PTSD improvements after MDMA-assisted therapy, meaningful remission rates in treatment-resistant depression after a single high-dose psilocybin session, and large reductions in heavy drinking days in alcohol use disorder with psilocybin-assisted psychotherapy. I use those peer-reviewed trial results as a doorway into a bigger question: can psychedelics belong inside positive psychiatry, where we measure and treat well-being, meaning, connectedness, resilience, and flourishing rather than only “symptom scores”?  We start with definitions so we don’t confuse positive psychiatry with vibe-based optimism. Then we go deep on the neurobiology of psychedelic-assisted therapy, including 5-HT2A receptors, why intracellular receptor activation may matter, and how downstream pathways like BDNF TrkB and synaptogenesis connect to durable change. From there we zoom out to whole-brain dynamics: default mode network rigidity, desynchronization, the entropic brain hypothesis, and why a short-lived drug effect can open a longer “window” for rewiring rigid self-stories.  Finally, we apply the framework to real clinical domains: psilocybin for depression (including head-to-head comparisons with an SSRI where secondary outcomes like flourishing and connectedness stand out), MDMA for PTSD and the realities of FDA review, psilocybin for addiction recovery, and the cancer distress data that helped launch the current psychedelic renaissance. We also tackle the most philosophically charged finding in the field: mystical-type experience as a measurable predictor of benefit, plus why therapeutic alliance, screening, and clinical rigor decide whether this becomes medicine or hype.  I www.JainUplift.com

A Doberman named Bear gets so excited for dinner that his legs buckle and he collapses, fully awake, staring at the food bowl he can’t reach. That strange, heartbreaking moment turns out to be a clean window into one of the brain’s most important control systems: orexin (also called hypocretin), a tiny hypothalamic signal that keeps wakefulness stable and prevents REM sleep features from intruding into the day. We walk through the Hollywood-worthy science, from the 1998 discovery race that produced two names for the same molecule to the Stanford narcoleptic dog colony that helped link orexin signaling to cataplexy. Then we build the neurobiology from the ground up: where orexin neurons live in the lateral hypothalamus, how OX1R and OX2R receptors shape arousal, and why the flip-flop switch model makes narcolepsy type 1 feel like a “flickering” between brain states. If you’ve ever wondered why cataplexy is often mistaken for seizures or “psychogenic” events, this framework makes the clinical picture click. From there, we go practical. We break down narcolepsy type 1 features (excessive daytime sleepiness plus cataplexy, often with sleep paralysis and fragmented nighttime sleep), the autoimmune story and the H1N1-era natural experiment, and the biggest news of all: the FDA approval of oviporextin (Orzifol), the first orexin receptor agonist designed to restore missing orexin signaling. We also flip the lens to insomnia, comparing DORAs like suvorexant, lemborexant, and daridorexant to older sedatives, and we close with orexin’s expanding relevance to depression, anxiety, addiction, and hyperarousal through reward circuitry. www.JainUplift.com

A magnetic coil on the scalp is the least interesting part of TMS. What hooked us in this conversation is the “how” a millisecond pulse becomes a durable shift in depression, anxiety, and even the stuckness of rumination and anhedonia, and why that maps so cleanly onto positive psychiatry and the pursuit of wellness, not just fewer symptoms. We start with the core biophysics: a rapidly changing magnetic field crosses the skull and, by Faraday’s law, induces an electric field in the superficial cortex. From there, we build a practical framework for understanding transcranial magnetic stimulation across nested levels of biology and time scales, from immediate cortical depolarization to circuit engagement in the dorsolateral prefrontal cortex, to large-scale network reorganization in systems like the default mode network and cognitive control network. Along the way, we make a key distinction that clears up a lot of confusion: the stimulation site is often an entry point, while the therapeutic target is the network. Then we get specific about what makes protocols different and why “dose” is more than minutes under the coil. We talk frequency as a biological message, including classic 10 Hz rTMS, inhibitory low-frequency approaches, and theta burst stimulation that can compress treatment while staying biologically efficient. We also zoom down to synapses and molecules, connecting glutamate signaling, NMDA and AMPA dynamics, calcium cascades, and BDNF-driven neuroplasticity, plus the roles of dopamine and GABA in motivation, reward, and the excitation-inhibition balance. We wrap by tying these mechanisms to longer-range changes in stress biology (HPA axis) and inflammation, and why TMS often works best as an augmenter alongside psychotherapy and medication. I hope this helped you think about TMS in a clearer, more hopeful way - and toview it from a Positive Psychiatry lens!  www.JainUplift.com

Your patient tells you, “The darkness is gone… but the color is gone too.” That line captures a problem many of us recognize: symptom scores can look great while real life still feels flat. From Texas, I walk through the positive psychiatry question that keeps nagging at clinicians and patients alike: are we only stopping the storm, or are we helping people experience the full spectrum of their lives again?  We get specific about the “SSRI blight” and why emotional blunting, apathy, and cognitive fog can linger even when PHQ-9 and GAD-7 say “remission.” I argue for expanding our outcomes beyond symptom reduction to measures that reflect functioning and flourishing: focus, executive function, relationships, hobbies, resilience, and joy. That’s where the “forgotten antidepressants” come back into view.  We shine a spotlight on vortioxetine (Trintellix) as a multimodal antidepressant with receptor activity that may support cognitive clarity and executive functioning for the right patient, and we break down vilazodone (Viibryd) as a SPARI with a more calibrated serotonergic signal that can be a strong fit for anxious depression and rumination. We also talk honestly about the GI side effects that scare people off, and how practical steps like slower titration, patient education, and taking vilazodone with a substantial meal can make a real difference.  Clinicians and patients are both motivated to find the tools that move us from “better” to truly “well.” www.JainUplift.com

GLP-1 medications are everywhere right now, but the most important conversation might be the one we are not having loudly enough: what do GLP-1 receptor agonists do to the brain? I go full geek mode on the neurobiology behind incretin mimetics and why semaglutide and tirzepatide may end up mattering to psychiatry as much as they matter to endocrinology. We start with anatomy and access. Endogenous GLP-1 is produced in the gut, but it is also produced by neurons in the brainstem and projected into regions that shape mood, anxiety, memory, and reward. From there, we explore how exogenous GLP-1 drugs can influence the central nervous system through selective blood-brain barrier entry points and vagal afferent pathways, and why receptor “real estate” in the hippocampus, amygdala, VTA, and nucleus accumbens changes the clinical story. Then we dive into mechanisms that matter for positive psychiatry: intracellular signaling (cAMP, kinases, CREB), neurotrophic support through BDNF, and the promise of neuroplasticity as more than a buzzword. We also unpack neuroinflammation and microglia, including how GLP-1 signaling may suppress inflammatory cascades, reduce oxidative stress, and create conditions where cognition and emotional regulation can recover. Finally, we connect GLP-1 to “food noise,” maladaptive salience, and dopamine spiking, highlighting how better top-down executive control could translate into real-world agency without blunting joy in most individuals. www.JainUplift.com

Your brain doesn’t just need more “happy chemicals.” It needs stability. We zoom in on GABA, the primary inhibitory neurotransmitter, and make the case that it’s one of the most overlooked keys to calm, clarity, resilience, and true mental health. We break down the neurobiology without the fluff: how GABA is made through the GABA shunt, how GABA-A and GABA-B receptors shape phasic and tonic inhibition, and why the excitatory-inhibitory balance between glutamate and GABA forms the functional backbone of the brain. From there, we connect the science to lived experience through the idea of “network flurry” the noisy, overdriven brain state that can show up in major depression, generalized anxiety, panic, PTSD, chronic stress, and the feeling that your mind simply won’t shut off. We also get practical about treatment. We examine how benzodiazepines and Z-drugs amplify GABA-A signaling, why they can bring fast relief, and why tolerance, dependence, sedation, and cognitive effects can work against long-term flourishing for many people. We clarify what gabapentin and pregabalin actually do (they are not direct GABA receptor drugs), then explore the emerging promise of neuroactive steroids like allopregnanolone and medications such as brexanolone and zuranolone for rapid antidepressant effects, including postpartum depression. To round it out, we highlight non-medication tools that support GABA function: mindfulness meditation, prayer, yoga, structured breath work like box breathing, exercise, and nutrition that supports healthy neurotransmitter synthesis. Let's hink differently about anxiety, depression, sleep, or stress. www.JainUplift.com

We launch a 'Psychiatry Journal Club' series built to get us reading again and to translate major psychiatry papers into practical, humane care.  We walk through four landmark studies that reshape how we think about schizophrenia treatment, suicidal crisis care, metabolic health, and relapse prevention through a Positive Psychiatry lens.  • why dopamine-first antipsychotics often miss negative symptoms and cognition while harming metabolic health  • how xanomeline plus trospium (KarXT/Cobenfy) targets M1 and M4 muscarinic receptors without direct D2 binding  • what the Emergent 3 phase 3 trial shows on PANSS change, onset by week two, and a cleaner metabolic and EPS profile  • why preserving reward circuitry and reducing dysphoria can change adherence conversations in schizophrenia  • the clinical gap between acute suicidality and multi-week SSRI and SNRI latency  • how intranasal esketamine rapidly affects glutamate circuits, AMPA signaling, mTORC1, and BDNF-driven synaptogenesis  • Aspire 2 outcomes at four hours and 24 hours, plus monitoring for dissociation and blood pressure changes  • how GLP-1 receptor agonists can reverse antipsychotic-induced weight gain and improve BMI, waist circumference, glucose, and lipids  • brain-gut-reward and neuroinflammation pathways that connect GLP-1s to neuropsychiatry  • why early long-acting injectables reduce relapse risk, hospitalizations, and functional decline in early schizophrenia  • how relapse biology and oral medication level swings support a neuroprotection argument for LAIs  Let’s together keep reading. We must read more, folks.  www.JainUplift.com

Your brain is built to detect danger fast, but it is also built to learn, adapt, and recover. We explore resilience through the lens of positive psychiatry and modern neuroscience, starting with a simple image: a three-story house in the mind. The basement is the amygdala, your smoke alarm. The second floor is the hippocampus, your memory librarian. The penthouse is the prefrontal cortex, the executive center that brings logic, planning, and emotional regulation back online. Resilience is not “never feeling stress.” It’s how quickly and smoothly your executive brain can send an all-clear signal when life hits. From there, we get concrete. We walk through the science of neuroplasticity and why BDNF, brain-derived neurotrophic factor, matters for building a more resilient brain over time. Then we lay out five biological pillars that act like a protective shield for your nervous system: optimized sleep, mindful movement, targeted nutrition through the gut-brain axis, mindfulness and meditation to reduce rumination, and deep social connection to buffer stress physiology. You’ll also hear why trying to change everything at once can trigger burnout, and how to pace your habits so they actually stick. Finally, we share a practical tool you can use when the walls feel like they’re closing in: the ABCDE cognitive model (Adversity, Belief, Consequences, Disputation, Energize). We connect it to the bigger goal of post-traumatic growth: not just bouncing back, but bouncing higher with deeper relationships, clearer priorities, new possibilities, stronger inner confidence, and meaningful spiritual change. www.JainUplift.com

Most mental health care starts with symptoms and medications, but too often it stops there. We wanted a more complete map, so we sat down with Dr. Lori Kumar, a psychiatric nurse practitioner serving community mental health patients across Austin and Central Texas rural areas, to talk about how positive psychiatry can fit into the real world of 20 to 30 minute visits, crisis follow-ups, and heavy med lists. We get specific about timing and language: when a person is still in crisis, safety and stabilization come first, but once things settle, we can shift toward mental wellness and patient agency. Lori shares a simple way to reduce confusion and resistance by using a medical analogy like asthma: medication matters, and so do the daily behaviors that calm the system and reduce triggers. From there, we dig into the practical pillars she returns to again and again, especially sleep wellness. Instead of reflexively reaching for sedation, we talk routines, realistic boundaries around phone use, and why “sleep hygiene” has to match modern stress and modern screens. We also unpack one of the best re-frames we have heard in years: if “exercise” makes patients shut down, call it movement. You will hear concrete, doable options for older adults, anxious patients, and anyone with low energy, plus low-cost cognitive training ideas like puzzles and word searches. We finish with gratitude practice that feels real, including a free app recommendation (“I Am”) that sends prompts throughout the day, and we connect all of this to clinician burnout and sustainability. www.JainUplift.com

If you’ve ever heard “norepinephrine” and instantly pictured panic, racing heart, and fight-or-flight, we’re about to flip that story. We make the case that norepinephrine is not just a stress chemical, it’s one of the brain’s most important tools for attention, cognitive control, resilience, and even post-traumatic growth when it’s regulated well.  We start with the big problem in mainstream psychiatry: a deficit framework that treats symptom reduction as the finish line. From a positive psychiatry lens, the real target is human flourishing. That brings us to the locus ceruleus, the tiny brainstem hub that provides most of the brain’s norepinephrine and acts like a master conductor for brain state. We break down tonic versus phasic firing, why the Yerkes-Dodson curve still matters, and how the “sweet spot” supports focus and flow without tipping into chaotic hyperarousal.  From there, we zoom into receptor dynamics and the tipping point where too much norepinephrine can shut down the prefrontal cortex and trigger an amygdala hijack. We connect the dots across the neurochemical ecosystem: norepinephrine’s tight relationship with dopamine in the prefrontal cortex, serotonin’s role as a natural dampener, and how downstream signaling can influence BDNF, neuroplasticity, and adult neurogenesis. Finally, we translate the science into real life by contrasting involuntary distress with voluntary stress, and showing how controlled challenges, exercise, cold exposure, mindfulness, and psychotherapy can “train” the system like weightlifting for the brain.  www.JainUplift.com

Trauma doesn’t just hurt; it reorganizes. It reshapes sleep, memory, attention, stress physiology, trust, identity, and the story you tell yourself about what life allows. That’s why I start from one non-negotiable place: respect for suffering. And I make one crucial distinction that changes how we think about trauma recovery and PTSD treatment, especially for complex PTSD: change is not the same thing as damage. POST TRAUMATIC GROWTH: We then take on a topic that’s often misused and often feared: post-traumatic growth. I’m not talking about silver linings, forced resilience, or spiritual bypassing. I’m talking about a careful, trauma-informed inquiry into what can become possible after survival, and why “getting back to who you were” can be an unrealistic and painful goal for many people. We walk through the neuroscience of growth after trauma, including the default mode network and meaning making, the salience network and threat-based attention, executive control, and why neuroplasticity needs safety to move in a healing direction. On the clinical side, I dig into timing, readiness, and language. Growth introduced too early can harm. Growth demanded can shame. Growth framed carelessly can invalidate grief. I share practical ways to listen for readiness, how to invite complexity without imposing meaning, and why growth can coexist with distress. We also talk moral injury, relationships as co-regulation, existential reframing without coercion, and the inner work clinicians need to do to avoid burnout while staying human. www.JainUplift.com

Glutamate is everywhere in the brain, but we’ve treated it like an afterthought. Rakesh Jain, MD, MPH joins us with a bold, clinically grounded argument: if we want real progress in depression, PTSD, anxiety, schizophrenia, OCD, addiction, and chronic pain, we have to understand glutamate as the main network driver, not just another neurotransmitter on a list.  We talk through why glutamate is both essential and dangerous, and why the right model isn’t “raise it” or “lower it,” but regulate it across regions and across time. Rakesh explains the two glutamate patterns that matter for symptoms, the overlooked role of glia and astrocytes, and the dizzying complexity of NMDA and AMPA receptors that makes one-size-fits-all treatment a fantasy. We also connect glutamate to brain circuitry, including default mode network rigidity in depression and the switching role of salience and executive networks.  Then we get practical and future-facing: what ketamine may be doing (including replicated evidence of opioid involvement), why durability remains a challenge, and why the field is shifting from NMDA to AMPA, mTOR, BDNF, and other neuroplasticity pathways. We explore classic psychedelics as rapid glutamate modulators, the rise of plastogens and biased 5-HT2A agonists, surprising links between GLP-1 agonists and glutamatergic control, and why neuromodulation depends on glutamate signaling. We close with a needed corrective: exercise, mindfulness meditation, sleep, and psychotherapy are not “extras” but powerful glutamate interventions.  www.JainUplift.com

What if the missing piece in mental health care isn’t more gravity—but more gentle levity? We take you inside the science of humor as a core psychological skill, not a distraction or denial. Drawing on research in positive psychiatry, Dr. Rakesh Jain explains how healthy humor works at the neural level to restore flexibility, ease anhedonia, and strengthen connection without minimizing pain. We break down the mechanisms that make humor a biologically efficient intervention. From benign prediction errors that light up dopaminergic pathways to shared laughter that triggers endogenous opioids, you’ll hear how the brain’s reward, salience, and stress systems recalibrate when we engage with lightness. We also dig into cortisol reduction, attention widening, and immune shifts that show humor’s impact is measurable—not just metaphorical. Expect practical tools you can use right away. Learn the difference between passive humor (borrowing joy through short, intentional exposure) and active humor (training attention to notice irony and play), why “sip, don’t binge” protects presence, and how the Three Funny Things exercise can boost mood for months after just a week. We also draw a firm line between affiliative humor that bonds and aggressive humor that harms, so you can use humor as a bridge, not a weapon. We close with an honest look at clinician well-being. Burnout and humor rarely coexist, and cultivating lightness—respectfully, safely—can help us show up better for our patients and ourselves. Subscribe, share this with a colleague who could use a lift, and leave a review with one amusing moment you noticed today. Your story might become someone else’s borrowed joy. www.JainUplift.com